Headinvest LLC Has $2.98 Million Stake in Celgene Corporation (CELG)

Headinvest LLC raised its position in shares of Celgene Corporation (NASDAQ:CELG) by 0.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,945 shares of the biopharmaceutical company’s stock after buying an additional 140 shares during the period. Headinvest LLC’s holdings in Celgene Corporation were worth $2,980,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CELG. Motco increased its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new position in Celgene Corporation during the first quarter valued at about $118,000. Carroll Financial Associates Inc. increased its position in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares during the last quarter. Oakworth Capital Inc. increased its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the last quarter. Finally, Acropolis Investment Management LLC bought a new position in Celgene Corporation during the second quarter valued at about $144,000. Hedge funds and other institutional investors own 78.34% of the company’s stock.

Celgene Corporation (CELG) traded up 0.05% during midday trading on Friday, hitting $127.65. 4,270,548 shares of the stock were exchanged. The company has a market capitalization of $99.87 billion, a P/E ratio of 39.53 and a beta of 1.89. The company’s 50 day moving average is $133.74 and its 200 day moving average is $124.92. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same period last year, the firm posted $1.44 earnings per share. Analysts predict that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Headinvest LLC Has $2.98 Million Stake in Celgene Corporation (CELG)” was originally published by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/20/headinvest-llc-buys-140-shares-of-celgene-corporation-celg-updated-updated-updated.html.

Several brokerages have recently weighed in on CELG. Jefferies Group LLC set a $154.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Saturday, May 13th. BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and lifted their target price for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target on the stock in a research report on Thursday, August 10th. Robert W. Baird restated an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a research report on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $147.00.

In other news, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Insiders sold 253,761 shares of company stock worth $33,792,445 over the last three months. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply